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Abstract 
En route towards improved delivery systems for targeted chemotherapy, we propose a straightforward 
approach for the hydrophobic modification of the acrylamide N-(2-hydroxyethy)acrylamide (HEAm). 
An ethyl or benzyl group was introduced via a hydrolytically sensitive carbonate ester yielding HEAm-
EC and HEAm-BC, respectively. Block copolymers of HEAm, respectively PEG and HEAm-EC or 
HEAm-BC were successfully synthesized by reversible addition-fragmentation chain transfer (RAFT) 
polymerization, obtaining a library of well-defined block copolymers with different degrees of 
polymerization (DP). To further explore the versatility of our approach in terms of polymer synthesis, 
self-assembly, drug solubilization and in vitro cell interaction, polyethylene glycol (PEG) and 
polyHEAm as hydrophilic polymer blocks were compared. The block copolymers formed micellar 
nanoparticles (10-100 nm) in PBS and could efficiently solubilize hydrophobic dyes and anti-cancer 
drugs. Benzyl carbonate ester side chains increased micellar stability and drug loading capacity. 
Moreover, PEG as hydrophilic block showed in comparison to HEAm more promising results 
concerning both colloidal stability and drug loading capacity. Confocal microscopy showed that the 
micelles could efficiently deliver a hydrophobic dye inside the cells. Finally, we also demonstrated 
efficient formulation of the anti-cancer drug paclitaxel with an in vitro cancer cell killing performance 
comparable or even better than the two commercial PTX nanoformulations Abraxane and Genexol-
PM at equal drug dose. In conclusion, modification of HEAm through carbonate linkages offers a 
versatile platform for the design of degradable polymers with potential for biomedical applications. 
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1. Introduction 
In the past decades, polymeric micelles have been extensively studied as drug delivery carriers for poorly 
water-soluble drugs. Moreover they are of great interest because of their high loading capacity, size (10-
100 nm), biocompatibility and chemical versatility.1,2,3,4,5 Polymeric micelles, which consist of a hydrophilic 
outer shell and hydrophobic inner core, are attractive systems for the delivery of a drug payload to tumors 
via a combination of targeting, mediated by active – ligand-receptor interactions and by passive enhanced 
permeability and retention (EPR) effect6. The former aims at enhancing the delivery to cancer cells that 
overexpress a specific receptor. The latter, first reported in 1986 by Maeda et al7, allows extravasation 
and retention of the micelles in tumor tissue, which in turn leads to higher drug concentration and 
increased therapeutic efficacy.8–10  
En route towards improved delivery systems for targeted chemotherapy we previously reported on the 
modification of N-(2-hydroxypropyl)methacrylamide (HPMA) with an ethyl group via a hydrolytically 
sensitive carbonate ester (i.e. HPMA-EC) which was polymerized by free radical polymerization (FRP)  
using a PEG-based macroinitiatior.11 Introduction of a hydrophobic moiety onto the hydroxyl group of 
HMPA renders the corresponding polymers more hydrophobic which could be used as driving force for 
temperature-induced self-assembly into micelles of PEG-poly(HPMA-EC) block copolymers in aqueous 
medium. Moreover, hydrolysis of the carbonate esters afforded fully soluble polymers, suggesting 
transiently thermoresponsive5 properties of the polymers 
Here, we vastly expand upon our previous work on different levels. On the level of the route of 
polymerization we elaborate in the present work on controlled radical polymerization rather than FRP due 
to the limited control on polymer molecular weight and molecular weight distribution offered by FRP. 
Reversible addition-fragmentation chain transfer (RAFT) polymerization is more favorable to obtain 
polymers with controlled molecular weight, low dispersity and end-group functionality9,12.  
On the monomer level we devised an alternative strategy for the synthesis of carbonate-modified 
hydroxyl-containing monomers which allowed us to extent our approach to acrylamides, which were 
previously inaccessible due to the occurrence of Michael addition as a side reaction. The use of 
acrylamides yields access to well defined block copolymers which – at least in our hands – could not be 
obtained by methacrylamides, which showed, in particular when attempting block copolymer synthesis, 
slow polymerization kinetics and limited end group fidelity. Similarly mixed success with RAFT block 
copolymerization of methacrylamides has also been reported by other groups.13–15 Therefore we opted in 
this work to elaborate on the use of N-(2-hydroxyethyl)acrylamide (HEAm) as monomeric scaffold for 
modification at its hydroxyl position with carbonate esters.  
Third, we propose in the present work the modification of HEAm with ethyl – yielding HEAm-EC – and 
benzyl – yielding HEAm-BC – side chain via a carbonate ester. The use of an ethyl side chain extends 
onto previously reported strategy for HPMA modification to the level of acrylamides, whereas benzyl 
modification is a new avenue we explore in this work to render the micelles more stable by promoting 
hydrophobic interactions in their core. The latter should increase micellar stability and drug loading 
capacity, due to π-π stacking of the aromatic groups, which was also demonstrated by Shi et al. 16,17 
Starting from respectively ethanol and benzyl alcohol that are tethered to HEAm via a carbonate ester 
moiety, we aim at the design of polymeric building blocks that are degradable into the same benign 
products that should not pose issues of long term accumulation in the body.  
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In a first attempt to evaluate the potential of these materials in a biomedical context, we synthesized block 
copolymers composed of HEAm-EC, respectively HEAm-BC, as hydrophobic block and several types of 
hydrophilic polymer blocks to explore the versatility of our approach in terms of polymer synthesis, self-
assembly, drug solubilization and in vitro cell interaction.  
 
 
2. Experimental section 
2.1. Materials 
All chemicals were purchased from Sigma Aldrich unless mentioned otherwise. The RAFT-CTA 2-
(butylthiocarbonothioylthio)propanoic acid (PABTC) was synthesized according to literature.18 TLC plates 
were purchased from Macherey Nagel. Dulbecco’s Phosphate-buffered saline (DPBS) (pH 7.4, 0.14 M 
NaCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4 * 7 H2O) was purchased from Thermo Fisher Scientific.  
Paclitaxel (PTX) was obtained from LC Laboratories. Octadecyl Rhodamine B Chloride (R18), enzyme-
free Cell Dissociation Buffer, Dulbecco’s Modified Eagle Medium (DMEM), fetal bovine serum (FBS), L-
glutamine, sodium pyruvate, penicillin, streptomycin, Hoechst, Alexa Fluor 488 and Phalloidin were 
obtained from Invitrogen. SKOV-3 cells were supplied by ATCC.  
2.2. Instrumentation 
1H-Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker 300 MHz FT-NMR 
spectrometer using CDCl3 and d6-DMSO as solvents. Chemical shifts (δ) are given in ppm relative to 
TMS. 
Electron spray ionization-mass spectroscopy (ESI-MS) was carried out on a Waters LCT Premier XETM 
TOF mass spectrometer with a ZsprayTM source and ESI and modular LocksprayTM interface, coupled 
to a Waters alliance HPLC system.  
Size exclusion chromatography (SEC) was performed on a Shimadzu 20A system, equipped with a 20A 
ISO-pump and a 20A refractive index detector (RID). Measurements were executed in N,N-
dimethylacetamide (DMA), containing 50 mM LiBr at 50 °C with a flow rate of 0.700 mL/min. Samples 
were run with toluene as an internal standard. Calibration of the 2 PL 5 μm Mixed-D columns was done 
with polymethylmethacryate (PMMA- standards) obtained from PSS (Mainz).  
Dynamic light scattering (DLS) was performed on a Zetasizer Nano S (Malvern Instruments Ltd., Malvern, 
U.K.) equipped with a HeNe laser (λ = 633 nm) and detection at scattering angle of 173°. Cumulants 
analysis of the data gave the z-average and polydispersity index and data fitting by CONTIN the particle 
size distribution. PBS was used as buffer.  
Fluorescence spectroscopy was carried out on a Cary Eclipse fluorescence spectrophotometer (Agilent 
Technologies) equipped with a Varian Cary Temperature Controller.   
Turbidimetry measurements were performed in a CARY Bio 100 UV–VIS spectrophotometer equipped 
(Agilent Technologies, Santa Clara, CA, USA) with a temperature controller, at a wavelength of 700 nm. 
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Heating/cooling cycles were performed at a rate of 1 °C/ min with stirring. The polymer concentration was 
kept at 5 mg/mL in PBS  
Confocal microscopy images were recorded on a Leica DMI6000 microscope coupled to an Andor DSD2 
scanner and a Zyla5.5 CMOS camera. 2D cell cultures were imaged with a 1.40 NA 63x oil immersion 
objective. 3D spheroids were imaged with a 10 x objective. Images were processed with ImageJ. 
High-performance liquid chromatography (HPLC) analyses were done on a system with an isocratic 
solvent pump (L-7100, Merck, Hitachi LaChrom, Tokyo, Japan) set at a flow rate of 1 mL/min, an 
autosampler (L-7200, Merck, Hitachi LaChrom, Tokyo, Japan) with a loop of 100μL, a guard column (RP 
18e) followed by a reversed phase C18 column (LiChroCart® 250-4, LiChrospher® 100 RP (5 μm)) and 
a UV-detector (L-7400, Merck, Hitachi LaChrom, Tokyo, Japan) set at a wavelength of 207 nm. The 
mobile phase consisted of water/acetonitrile (60/40) and the injection volume was set at 10 μL. 
Ultra-performance liquid chromatography (UPLC) analyses were carried out using Waters Acquity system 
consisting of a binary solvent manager, a sample manager and a UV detector. An Acquity UPLC BEH 
C18 1.7 μm column (2.1 x 50 mm) was used with a column temperature of 50°C. The mobile phase 
consisted of acetonitrile/water 45/55 (v/v), supplemented with 0.1% (v/v) trifluoroacetic acid at a flow rate 
of 1 mL/min. 
2.3. Synthesis of HEAm-BC  
The synthesis of HEAm-BC was performed in 2 steps and was based on the protocol for the synthesis of 
HEMA-CI and HPMA-EC.11,19 First, a round-bottom flask was filled with 1,1’-carbonyldiimidazole (CDI) 
(4.86 g, 30.0 mmol) and 25 mL anhydrous dichloromethane under a nitrogen atmosphere. Subsequently, 
benzylalcohol (2.07 mL, 20.0 mmol) was added after which a clear solution was obtained. After 2 h stirring 
at room temperature, the reaction mixture was transferred into a separatory funnel and washed with water. 
The dichloromethane layer was dried over MgSO4 and filtered. The solvent was removed under reduced 
pressure, yielding the activated monomer as yellow oil (quantitative). 1H-NMR activated benzylalcohol 
(BC-CI) (CDCl3, 300 MHz), δ (ppm): 8.07 (s, 1H, imi-H), 7.36 (m, 6H, imi-H, benzyl-H), 6.99 (s, 1H, imi-
H), 5.35 (s, 2H, C-CH2).  
In the next step the activated benzylalcohol (4.30 g, 21.26 mmol) was dissolved in 10 mL anhydrous DMF 
under a nitrogen atmosphere. N-(2-hydroxyethy)acrylamide (HEAm, 4.896 g, 42.52 mmol), also dissolved 
in anhydrous DMF, was added dropwise. Note that HEAm contained 1,000 ppm monomethyl ether 
hydroquinone as inhibitor, which proved sufficient to prevent autopolymerization. Moreover, we confirmed 
by 1H-NMR, that after rotary evaporation of the reaction mixture, but before manual column 
chromatography purification, no autopolymerization occurred. The reaction mixture was stirred overnight 
at 80 °C. Afterwards the solvent was evaporated under reduced pressure and the product was redissolved 
in dichloromethane. The dichloromethane layer was washed with 1M HCl in water to remove formed 
imidazole.  The dichloromethane layer was dried over MgSO4 and filtered. Lastly, the residual reaction 
mixture was purified using silicagel column chromatography (eluent dichloromethane/ethyl acetate – 9/1 
(v/v)) (yield: 60%) 1H-NMR HEAm-BC (CDCl3, 300 MHz), δ (ppm): 7.32 (m, 5H, benzyl-H), 6.21 (dd, 1H, 
CH2=CH), 5.99 (dd, 1H, CH2=CH), 5.86 (br, 1H, NH), 5.58 (dd, 1H, CH2=CH), 5.10 (s, 2H, OCH2C), 4.20 
(t, 2H, OCH2CH2), 3.56 (q, 2H, OCH2CH2). ESI-MS C13H14NO4: calculated [M + H]+ 250.10738,  [M + Na]+ 
272.08932, [M + K]+ 288.06326, found [M + H]+ 250.1062, [M + Na]+ 272.0881, [M + K]+ 288.0615.  
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2.4. Synthesis of HEAm-EC  
A round-bottom flask was filled with 1,1’-carbonyldiimidazole (CDI) (4.86 g, 30.0 mmol) and 25 mL 
anhydrous dichloromethane under a nitrogen atmosphere. Subsequently, ethanol (1.17 mL, 20.0 mmol) 
was added after which a clear solution was obtained. After 2 h stirring at room temperature, the reaction 
mixture was transferred into a separatory funnel and washed with water. The dichloromethane layer was 
dried over MgSO4 and filtered. The solvent was removed under reduced pressure, yielding the activated 
monomer as a clear oil (quantitative). 1H-NMR activated ethanol (Et-CI) (CDCl3, 300 MHz), δ (ppm): 8.07 
(s, 1H, imi-H), 7.36 (s, 1H, imi-H), 7.00 (s, 1H, imi-H), 4.42(q, 2H, CH2-CH3), 1.37 (t, 2H, CH2-CH3).  
In the next step the activated ethanol (2.98 g, 21.26 mmol) was dissolved in 10 mL anhydrous DMF under 
a nitrogen atmosphere. N-(2-hydroxyethy)acrylamide (4.896 g, 42.52 mmol), also dissolved in anhydrous 
DMF, was added dropwise. The reaction mixture was stirred overnight at 80 °C. Afterwards the solvent 
was evaporated under reduced pressure and redissolved in dichloromethane. The dichloromethane layer 
was washed with 1M HCl in water to remove formed imidazole.  The dichloromethane layer was dried 
over MgSO4 and filtered. Lastly, the residual reaction mixture was purified using silicagel column 
chromatography (eluent dichloromethane/ethyl acetate – 8/1 (v/v)) (yield: 60%) 
1H-NMR HEAm-EC (CDCl3, 300 MHz), δ (ppm): 8.07 (s, 1H, imi-H), 7.36 (s, 1H, imi-H), 7.00 (s, 1H, imi-
H), 4.42(q, 2H, CH2-CH3), 1.37 (t, 2H, CH2-CH3). ESI-MS C8H13NO4: calculated [M + H]+, 188.2023 [M + 
Na]+ 210.1842, [M + K]+ 226.1582, found [M + H]+ 188.0913, [M + Na]+ 210.0735, [M + K]+ 226.0479  
2.5. Monomer hydrolysis kinetics 
The monomer degradation kinetics were determined, based on a described protocol16. A 10 mM stock 
solution of HEAm-EC and HEAm-BC was prepared in DMSO. Next, 0.5 mL of the stock solution in DMSO 
was added to 4.5 mL of phosphate buffer (pH 7.4, 100 mM) or carbonate buffer (pH 10.0, 100 mM). The 
hydrolysis reactions were conducted at 37 °C in triplicate. At various time points, samples (50 μl) were 
drawn from the mixture and diluted with 950 μl phosphate buffer (pH 4.4, 100 mM) to stop any further 
degradation. The samples were stored at 4 °C until they were analyzed by HPLC. As eluent ACN/H20 
40/60 was used to determine the hydrolysis rate of HEAm-EC and HEAm-BC, with a flow rate of 0.2 
mL/min and a detection wavelenght of 207 nm. The degradation rate of HEAm-BC was estimated based 
on the calibration curve of the molar ratio of HEAm-BC and benzylalcohol. Degradation samples of HEAm-
EC were spiked with benzyl alcohol as internal standard because ethanol could not be detected, which 
allowed similar data analysis.  
2.6. Synthesis of pHEAm-EC/BC homopolymer. 
For the homopolymerization of HEAm-EC and HEAm-BC by RAFT polymerization, HEAm-EC, (2.5 mmol, 
0.468 g) respectively HEAm-BC (2.5 mmol, 0.623 g), 2-(butylthiocarbonothioylthio)propanoic acid 
(PABTC) (0.063 mmol, 14.9 mg) and AIBN (0.013 mmol, 2.05 mg) were dissolved in dry DMF (2M). A 
monomer/CTA/AIBN molar ratio of 40:1:0.2 was used. The reaction mixture was degassed with five 
freeze-pump-thaw cycles and the reaction was conducted at 70 °C for two hours under a vacuum 
atmosphere. The polymer was isolated by precipitation in cold diethyl ether, and subsequently dried under 
vacuum at room temperature. Monomer conversion was determined by 1H-NMR and polydispersity of 
purified polymer was analyzed by SEC. 
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2.6. Synthesis of poly(HEAm)xmacroCTA 
A macromolecular RAFT chain transfer agent (MacroCTA) was synthesized by RAFT 
homopolymerization of N-(2-hydroxyethy)acrylamide (HEAm). pHEAm64  was synthesized by dissolving 
PABTC (0.267 mmol, 63.6 mg), 2,2’-azobisisobutyronitrile (AIBN, 0.027 mmol, 4.38 mg) and HEAm (20 
mmol, 2.303 g) in N,N-dimethylformamide (DMF) to obtain a monomer concentration of 2.0 M and a 
monomer/CTA/initiator molar ratio of 75:1:0.1. The mixture was degassed by five freeze−pump−thaw 
cycles, and the reaction was performed at 70 °C for 2 h under vacuum. The obtained polymer was purified 
by triple precipitation in cold diethyl ether. After centrifugation, the residue was dried overnight under 
vacuum at room temperature. Finally, the polymer was dialyzed at 5 °C against distilled water (MWCO 
3.5 kDa) for 3 days and recollected after lyophilization. The homopolymer was analyzed by SEC and 1H-
NMR. The conversion of HEAm was determined by comparing the integration areas of the vinyl protons 
of unreacted HEAm at 5.30 ppm and the methylene group at 4,20 ppm. A similar protocol was used for 
the synthesis of pHEAM140, but with a monomer/CTA/initiator molar ratio of 200:1:0,1. 
2.7. Synthesis of pHEAm-pHEAmEC & -BC block copolymers 
pHEAm64 and pHEAm140 – macroCTA were used for the synthesis of 8 block copolymers with various 
chain lengths.  The second block was either composed of HEAm-EC or HEAm-BC.  Variations in chain 
length were obtained by changing the monomer/CTA/initiator molar ratio.  For the synthesis of pHEAm64-
pHEAmEC26, pHEAm64 (0.038 mmol, 285 mg), AIBN (0.008 mmol,1.23 mg) and HEAm-EC (1.2 mmol, 
225 mg) were dissolved in anhydrous DMF, with a final monomer concentration of 0.90 M and a 
monomer/CTA/initiator molar ratio of 32:1:0.2. The reaction mixture was degassed with five freeze-pump-
thaw cycles and the reaction was conducted at 80 °C for two hours under a vacuum atmosphere. The 
polymer was isolated by precipitation in cold diethyl ether, and subsequently dried under vacuum at room 
temperature. Finally, the polymer was dialyzed at 5 °C against distilled water (MWCO 3.5 kDa) for 3 days 
and recollected after lyophilization. The block copolymer was analyzed by 1H NMR and SEC.  
2.8. Synthesis of PEG-pHEAm-EC & -BC block copolymers 
Block copolymers of HEAm-EC/HEAm-BC and ethylene glycol were synthesized using a commercially 
available PEG-CTA (5 kDA). A monomer/CTA/AIBN ratio of 50:1:0.2 and 100:1:01 were used. PEG5000, 
HEAm-EC/HEAm-BC and AIBN were dissolved in DMF and degassed by five freeze-pump-thaw cycles.  
After 2 hours at 80 °C and under a vacuum atmosphere, the reaction was stopped by precipitation in cold 
diethyl ether.  After drying under vacuum at room temperature, the polymer was dialyzed (MWCO 3.5 
kDa) against distilled water for 3 days and recollected after lyophilization. The block copolymers were 
analyzed by 1H NMR and SEC.  
2.9. Micelle preparation 
Polymeric micelles of PEGx-pHEAmECy and pHEAmm-pHEAmECn were prepared by adding the polymers 
to PBS at a concentration of 5 mg/mL followed by sonication for 1 min to form micelles. PEGx-pHEAmBCy 
micelles were obtained by a nanoprecipitation technique, which involved dissolving 5 mg block 
copolymers in 1 mL THF.20 Next, this solution was added dropwise to PBS in a 1:1 ratio, while stirring. 
After evaporation of THF for 48 hours, nanoparticles were formed. pHEAmm-pHEAmBCn micelles were 
prepared by a dialysis method, where the blockcopolymers were dissolved in DMSO and dialyzed against 
PBS to trigger micelle formation. 
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2.10. Transmittance measurement  
The cloud point (CP) of pHEAm-EC was investigated by turbidimetric analysis. First the block copolymer 
was dissolved in ice-cold PBS at a concentration of 5 mg/mL. Turbidity of the solution was measured by 
the transmission at 600 nm through the sample vial as a function of the temperature while stirring. The 
sample was heated up from 5 to 40 °C with a heating rate of 1 °C/min. The cloud point was taken as the 
onset of the drop in transmittance in the turbidity curve.   
2.11. Polymer hydrolysis 
For monitoring the evolution of particle size during hydrolysis of the carbonate ester side chain moieties, 
pHEAmx-pHEAmECy/BCz and PEG-pHEAmECm/BCn were dissolved at 5 mg/mL in an aqueous 0.1 M 
NaOH solution (pH 13). Subsequently, particle size and light scattering intensity were measured at 37 °C 
at 15 min intervals.  
2.12. Critical Micelle Concentration (CMC) 
Dilution series of the block copolymers in PBS were prepared with concentrations ranging from 0.001-1 
mg/mL. Next, a stock solution of pyrene in acetone (1.8 x 10-2 M) was prepared and kept on ice to prevent 
evaporation of the acetone. The stock solution was then diluted (1/100) and also kept on ice. Finally, 6,67 
μL of the latter pyrene solution was added to 2 mL of each polymer dilution in triplicate under stirring 
(pyrene concentration 6.0 x 10-7 M). The polymer dispersions were vigorously vortexed and incubated 
overnight to promote particle formation and evaporate acetone. Fluorescence excitation spectra were 
recorded at room temperature with an excitation wavelength of 390 nm and monitored from 300-360 nm. 
The CMC was determined based on the change in excitation intensity ratio at 338 and 333 nm in function 
of the polymer concentrations.16,21 
2.13. Cell culture 
SKOV-3 (human ovarian cancer cell line) cells were cultured in DMEM, supplemented with 10% FBS, 2 
mM L-glutamine, 1 mM sodium pyruvate and antibiotics (50 units/mL penicillin and 50 µg/mL 
streptomycin). Cells were incubated at 37 °C in a controlled, sterile environment of 95% relative humidity 
and 5% CO2. SKOV-3 cells were used for all cell experiment.  
2.14. In vitro cellular uptake 
2.14.1. Encapsulation hydrophobic fluorescent dye. 
For the encapsulation of a hydrophobic, fluorescent dye, Octadecyl Rhodamine B Chloride was used.  
Octadecyl Rhodamine B Chloride was loaded into the nanoparticles using a solvent displacement 
technique. A small amount (100 μL) of an ethanolic solution (0.05 mg/mL) was added to the block 
copolymer dispersions in PBS (10 mg/mL) under stirring. As a control, the same ethanolic solution was 
added to pure PBS, leading to precipitation of the hydrophobic dye. Formulations were stabilized overnight 
at room temperature to allow evaporation of ethanol. The excess dye was removed by membrane filtration 
(0.450 µm).  
2.14.2. Confocal Microscopy 
Cells were plated in WillCo Wells dishes at a density of 5*103 cells per well and allowed to adhere 
overnight. Subsequently, cells were pulsed for 16 hours with micelles 5 μL of 10 mg/mL R18-labeled block 
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copolymers followed by washing with PBS and fixation with 4 % paraformaldehyde. Prior to imaging, cell 
nuclei were stained with Hoechst 33342 (according to manufacturer’s protocol) and the cell membrane 
was stained with AlexaFluor488-conjugated phalloidin. 
2.15. Drug loading 
Paclitaxel-loaded micelles of PEGx-pHEAmECy and pHEAmm-pHEAmECn were prepared by first 
dissolving the polymers in cold PBS at a concentration of 10 mg/mL. Next, a 10 mg/mL solution of PTX 
in acetone was prepared, and 100 μL of this solution was added to 1 mL of the cold (5 °C) polymer 
solution followed by rapid heating to 50 °C and sonication to allow for micelle formation. The formulation 
was allowed to stabilize overnight at room temperature, with the lid kept open to enable evaporation of 
the acetone. 
The encapsulation of paclitaxel into the PEGx-pHEAmBCy micelles, was carried out using the 
nanoprecipitation method.20 Therefore, 1 mg of paclitaxel and 10 mg of polymers were dissolved in 1 mL 
of THF en added drop wise to 1 ml PBS. After evaporation of THF for 48 hours, nanoparticles were 
formed.  
pHEAMm-pHEAmBCn loaded micelles were prepared by a dialysis method, where blockcopolymers (10 
mg) and paclitaxel (1 mg) were dissolved in 1 mL DMSO and dialyzed against PBS to trigger micelle 
formation and drug loading.  
Finally, the free drug was removed by filtration (0.450 μm) and the paclitaxel concentration loaded into 
the micelles was determined by UPLC analysis, similar to a described protocol.16 For this 100 μL of the 
PTX loaded micelle dispersion was diluted with 900 μL acetonitrile and vortexed to destabilize the micelles 
and fully dissolve the drug.  Next, this was centrifuged for 15 min. at 15000 g and 2 μL of the supernatans 
was injected. A calibration curve of PTX was prepared by dissolving PTX in acetonitrile in a concentration 
range of 2-100 μg/mL. PTX was measured at a wavelength of 227 nm and from the determined PTX 
concentration, encapsulation efficiency (EE) and loading capacity (LC) were calculated as follows: 
𝐸𝐸 =
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑃𝑇𝑋
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑑𝑑𝑒𝑑 𝑃𝑇𝑋
 𝑥 100% 
𝐿𝐶 =
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑃𝑇𝑋
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑃𝑇𝑋 + 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑑𝑑𝑒𝑑 𝑝𝑜𝑙𝑦𝑚𝑒𝑟
 𝑥 100% 
2.16. In vitro cytotoxicity  
In vitro cytotoxicity was determined using the MTT assay as described earlier.22,11 SKOV-3 cells were 
pulsed with different concentrations of PTX loaded micelles and as control nanoparticle formulations 
Abraxane (Celgene) and Genexol-PM (Samyang Biopharmaceuticals) were used. The MTT stock solution 
was prepared by dissolving 100 mg MTT in 20 mL of PBS and subsequent membrane filtration (0.22 μm). 
Before use, the MTT stock solution was 5-fold diluted with culture medium. 
SKOV-3 cells were seeded into 96-well titer plates (10000 cells per well, suspended in 200 μL of culture 
medium) and incubated overnight. Next, 50 μL of sample, DMSO (positive control = 0% viability) or PBS 
(negative control = 100% viability), was added to the cells, followed by 72 h of incubation. Subsequently, 
the medium was aspirated and the cells were washed with 200 μL of PBS. After aspiration, 100 μL of MTT 
working solution was added and the cells were incubated for 2.5 h. Finally, the MTT working solution was 
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aspirated and the formed purple formazan crystals were dissolved in 50 μL of DMSO. Absorbance was 
determined at 590 nm using an EnVision Multilabel plate reader. The absorbance of the positive control 
was used as a blank and therefore subtracted from all values. The dilution series, positive and negative 
control were added to the wells in triplicate (n=3). Cell viability (%) was calculated according to the 
equation below.  
𝑐𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
𝐴𝑏𝑠 (𝑠𝑎𝑚𝑝𝑙𝑒) − 𝐴𝑏𝑠 (+𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
𝐴𝑏𝑠 (– 𝑐𝑜𝑛𝑡𝑟𝑜𝑙) − 𝐴𝑏𝑠 (+𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
 𝑥 100% 
 
3. Results and discussion 
3.1 Monomer synthesis 
HEAm-EC and HEAm-BC were synthesized by modifying HEAm with an ethyl/benzyl group via a 
carbonate ester (FIgure 1). Our previously reported route for the synthesis of HPMA-EC11 involved 
activation of the hydroxyl group of HPMA with 1,1-carbonyldiimidazole (CDI) followed by a purification 
(extraction) step and subsequent reaction with a large excess of ethanol, affording the formation of a 
carbonate esters between the propylmethacrylamide moiety and the ethyl moiety. However, when this 
route was transposed to acrylamides, we faced extremely poor reaction yields due to Michael addition 
between the acrylamide moiety and the imidazole by-product that is formed during both reaction steps. 
Therefore, a crucial amendment to our previously reported synthesis was to first activated the hydroxyl 
group of ethanol/benzylalcohol, with (CDI) followed by a substitution reaction with HEAm, yielding 2-
acrylamidoethyl ethyl carbonate (HEAm-EC) and 2-acrylamidoethyl benzyl carbonate (HEAm-BC) 
respectively (Figure 1). In both these reaction steps, the formed imidazole acts as a catalyst, and did not 
require the use of an additional base catalyst. By opting for this synthesis route, Michael addition is 
reduced between the α,β unsaturated carbonyl moiety of HEAm and imidazole, and affords yields up to 
60 % for both monomers. 1H-NMR and MS analysis of the synthesized monomers are shown in Figure 
S1-S4. 
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FIGURE 1: Synthesis of (A) HEAm-EC and (B) HEAm-BC. (C) Schematic representation of responsive block copolymer 
micelles. 
 
3.2. Monomer degradation kinetics 
The degradation kinetics of HEAm-EC and HEAm-BC were studied at pH 7.4, 9 and 10 at 37 °C by HPLC. 
The pH of 7.4 is representative of the physiological conditions and pH values of 9 and 10 were used to 
accelerate hydrolysis rate of the carbonate ester. Hydrolysis of the carbonate ester moiety results in 
liberation of CO2 and ethanol or benzyl alcohol, respectively. Whereas benzyl alcohol could be readily 
detected by HPLC, allowing to take the ratio of benzyl alcohol to HEAm-BC, ethanol could not be detected 
and therefore HEAm-EC degradation samples were spiked with benzyl alcohol as internal standard which 
allowed similar data analysis as for HEAm-BC. 
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FIGURE 2: A) Hydrolysis of HEAm-EC and HEAm-BC at pH 7.4, 9 and 10. (n=3) B) First order kinetics of monomer 
hydrolysis with –d(monomer)/dt = k * monomer, which leads to ln((monomer)t/(monomer)t=0) = -k * t  and (monomer)t 
= (monomer)t=0* e (-kt); k: rate constant for hydrolysis; half-life t1/2 = ln2 / k 
 
For both HEAm-EC and HEAm-BC, the rates of hydrolysis were similar and followed for each pH first 
order kinetics. The calculated rate constants and half-lives are listed in the adjacent Table 1. Hydrolysis 
was strongly affected by the pH of the medium with full hydrolysis of both monomers occurring in less 
than 2 days at pH 10, whereas about a week was required to fully degrade at pH 9 and very slow 
hydrolysis was measured at pH 7.4. 
 
Table 1: The calculated first-order reaction rate constants (k) and half lives t(1/2) at 37 °C and pH 7.4, 9 and 10 
 
pH kHEAm-BC (h-1) t(1/2)HEAm-BC (h) 
kHEAm-EC (h-1) t(1/2)HEAm-EC (h) 
7.4 
(74 ± 4) *10-5 (9.3 ± 0.8)*102 
0.0011 ± 0.0003 
(5.8± 2) *102 
9 0.053 ± 0.001 
13 ± 0.5 
0.022 ± 0.001 
32 ± 2 
10 0.14 ± 0.004 
5.0 ± 0.2 
0.089 ± 0.002 
7.8 ± 0.2 
 
3.3.  RAFT polymerization 
First we verified that HEAm-EC and HEAm-BC could be polymerized by RAFT. To this end, 2-
(butylthiocarbonothioylthio)propanoic acid (PABTC) was used as chain transfer agent (CTA) and AIBN as 
radical initiator. Anhydrous DMF was used as solvent to avoid hydrolysis of the carbonate esters. Size 
exclusion chromatography (SEC) analysis of the polymers showed a low dispersity (1.09 for both pHEAm-
EC19 as pHEAm-BC33) and 1H-NMR analysis indicated the experimental degree of polymerization (DP) to 
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correspond well to the theoretical DP (Table 2). Taken together, these findings demonstrate that both 
HEAm-EC and HEAm-BC can be successfully be polymerized by RAFT and yield well-defined polymers. 
 
Table 2: Compositional data of the synthesized polymers  
 Monomer CTA M:CTA Time (min.) Conversion 
(%)a 
DPa Mna 
(kDa) 
Mnb 
(kDa) 
Ðb Tcp 
(°C) 
pHEAmEC19 HEAm-EC PABTC 40:1 120 48 19 3.8 4.3 1.09 16 
pHEAmBC33 HEAm-BC PABTC 40:1 120 83 33 8.5 8.6 1.09 / 
aCalculated based on 1H NMR spectroscopy data. bDetermined by SEC in DMAc using PMMA for calibration. 
 
The thermo-responsive properties of pHEAm-EC19 were measured by turbidimetry at a polymer 
concentration of 5 mg/mL in phosphate buffered saline (PBS) (pH 7.4; 0.15 M NaCl). Samples were 
heated from 5 °C to 40 °C with a heating rate of 1 °C/min. The cloud point temperature (Tcp: i.e. the 
temperature at which the polymer precipitates from solution due to an entropically-driven coil-to-globule 
transformation) was determined to be 16 °C as evidenced by the drop in transmittance at 16 °C, which 
indicates phase separation. (Figure 3). The more hydrophobic pHEAMBC33 even at low temperature does 
not dissolve in water and therefore does not have LCST properties.  
 
 
                        
FIGURE 3: Transmittance versus temperature plot of pHEAm-EC19  
 
 
3.4.  Block copolymer synthesis 
Next, we synthesized amphiphilic block copolymers with poly(HEAm-EC), respectively poly(HEAm-BC), 
serving as hydrophobic block. As hydrophilic block, two different types of polymers were evaluated, i.e. 
poly(N-(2-hydroxyethyl)acrylamide) (poly(HEAm)) and poly(ethylene glycol) (PEG). PEG is a well-known 
stealth polymer and PEG with a molecular weights between 2-10 kDa, are often used as hydrophilic shell 
to provide colloid stability, evade opsonization by the reticuloendothelial system (RES) and hence 
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increase circulation half-life of nanomedicines.23,24,25 Poly(HEAm) has been less studied, but also 
possesses hydrophilicity and likely similar behavior as poly(HPMA) which is also known for its stealth 
properties26–28  
For the synthesis of a poly(HEAm) macro-CTA, we aimed at 2 different DPs, i.e. 75 and 200. A conversion 
of 85% and 70% was determined by 1H-NMR, which correspond to a final theoretical DP of 64 and 140 
respectively and a corresponding molecular weight of 7.6 and 16.4 kDa. SEC traces reveal a low 
dispersity (Ð) of 1.08 for poly(HEAm)64 and 1.10 for poly(HEAm)140, with a number average molecular 
weight (Mn) of 15.7 kDa and 23.5 kDa respectively. (Table 3) 
Next, the poly(HEAm)x-macroCTA’s were extended with different block lengths of the HEAm-EC, 
respectively HEAm-BC. The properties of the resulting block polymers are listed in Table 3. According to 
1H-NMR, conversions between 70-91% were obtained for the block copolymers after a reaction time of 
2h. SEC-traces (Figure 4) of the block copolymers show a shift to higher molecular weight values in 
comparison to the corresponding macro-CTAs, which confirm successful block copolymer formation. The 
dispersities of the polymers were low (< 1.2), except for the block copolymers based on the pHEAm140-
macroCTA, which were however still below 1.7. This can most likely be ascribed to the high DP of 
pHEAm140-macroCTA, which results in sub-optimal chain extension and limited control over the 
polymerization.  
For the synthesis of PEG-based block copolymers, we used a commercially available PEG macroCTA, 
i.e. poly(ethylene glycol) methyl ether 2-(dodecylthiocarbonothioylthio)-2-methylpropionate, with an 
average molecular weight of 5 kDa. The PEG macroCTA was extended with HEAm-EC, respectively 
HEAm-BC, aiming at a DP of 50 and 100.  Mn and Ð were measured by SEC and are listed in Table 3.  
SEC traces for all polymers show residual homopolymer of unconverted PEG-CTA. We ascribe the 
presence of unreacted macroCTA rather to the poor quality of the commercial source rather than poor 
control over the RAFT block copolymerization. To correct for the fraction of unreacted CTA, peak 
deconvolution was applied to the SEC data and the experimental DP was recalculated based on the 
conversion and the fraction of unreacted macroCTA. These values are also listed in Table 3. 
Figure 4: SEC traces of polymers before and after chain extension of the pHEAmx- en PEG-macroCTA with HEAm-
EC/HEAm-BC 
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TABLE 3: Compositional data for the synthesized polymers  
(macro)CTA Monomer (M) M/CTA/AIBN Conversion (%) DP MnSEC 
(kDa) 
Mntheo* 
(kDa) 
Ð Hydrophilic 
/hydrophobic 
ratio 
PABTC-CTA HEAm 75/1/0.2 85 64 15.7 7.6 1.08 / 
 HEAm 200/1/0.2 70 140 23.5 16.4 1.10 / 
     Poly(HEAm)64 HEAm-EC 32/1/0.2 81 26 18.2 12.5 1.11 0.41 
  80/1/0.2 70 56 19.0 18.1 1.13 0.88 
 HEAm-BC 32/1/0.2 78 25 15.9 13.8 1.11 0.39 
  80/1/0.2 85 68 21.8 24.6 1.23 1.063 
Poly(HEAm)140 HEAm-EC 100/1/0.2 88 88 31.9 32.7 1.22 0.63 
  200/1/0.2 80 160 37.2 46.3 1.31 1.14 
 HEAm-BC 100/1/0.2 91 91 32.9 39.1 1.39 0.65 
  200/1/0.2 86 172 35.6 59.3 1.67 1.23 
PEG5000 HEAm-EC 50/1/0.2 82 41 19.7 12.7 1.13 0.80 
  100/1/0.2 81 81 19.8 20.2 1.24 1.50 
 HEAm-BC 50/1/0.2 84 42 17.6 15.5 1.14 0.78 
  100/1/0.2 78 78 27.6 24.4 1.20 1.44 
* Calculated by 1H-NMR 
 
3.5. Self-assembly behavior in aqueous medium 
Next we aimed at investigating the influence of different chain lengths of the hydrophobic block on the 
self-assembly behavior of the block copolymers in aqueous medium. For the latter, different protocols 
were used due to the different solubility of the respective block copolymers. pHEAm-EC, which exhibits 
LCST behavior, allows for self-assembly by rapid heating in phosphate buffered saline (PBS; pH 7.4, 150 
mM NaCl) from below to above the cloud point temperature. This method has been described previously 
for self-assembly of thermoresponsive block copolymers by Soga et al.29 Due to hydrophobicity of 
pHEAm-BC, self-assembly was performed by solvent displacement (from THF or DMSO into PBS, 
depending on the solubility of the hydrophilic block) for both PEGx-pHEAm-BCy and pHEAmm-pHEAmBCn. 
Subsequently, particle size was measured by dynamic light scattering (DLS) at 25 °C. Volume size 
distributions are shown in Figure 5. From these data, it can be concluded that all block polymers self-
assemble into micellar nanoparticles with sizes between 10-100 nm and with low dispersity (<0.4) Table 
SI1. Nanoparticles within this size range are considered to be the ideal for long circulation in the 
bloodstream and diffusion into tumor tissue.30 Furthermore, an increase in particle size was observed with 
increasing hydrophobic content. However, we also observed that a too elevated HEAm-BC content did 
not allow for the assembly of well-defined structures as observed by a multimodal size distribution of block 
copolymers with a HEAm-BC DP of 192. 
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FIGURE 5: Volume size distribution histograms of the synthesized polymers measured by DLS. 
 
3.6. Polymer hydrolysis 
As described in section 3.2 the monomers HEAm-EC and HEAM-BC are degradable due to hydrolysis of 
the carbonate ester side chains. Therefore, block copolymer micelles based on these monomers should 
be converted into fully hydrophilic polymers upon prolonged exposure to aqueous medium. Hydrolysis of 
the carbonate esters liberates CO2 and ethanol/benzylalcohol as benign byproducts. This will facilitate 
renal clearance of the resulting polymers, providing their molecular weight is below 40 kDa31, which is the 
case in our present study, thereby preventing long-term accumulation in the body. To investigate 
hydrolysis-triggered disassembly of the micelles, the block polymers were dissolved in 0.1 M NaOH (pH 
13, i.e. accelerated degradation conditions) at 37 °C, and analyzed by DLS. Figure 6 shows a decrease 
in particle sizes upon exposure of the polymers under basic conditions, which indicates the formation of 
soluble unimers. In accordance to the hydrolysis rate of the monomers at physiological conditions, slow 
degradation rates at neutral pH are expected29.  
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FIGURE 6.  Hydrolysis of pHEAm64-pHEAmEC26 and pHEAm64-pHEAmBC25 in 0.1 M NaOH (PH 13), monitored by DLS 
 
3.7. Critical Micelle Concentration (CMC) 
The CMC of the polymers was determined using pyrene as fluorescent probe in PBS at 37°C according 
to a previously published method.22 Figure 7 depicts the excitation intensity ratio of pyrene at 338 nm (I3) 
and 333 nm (I1) versus the polymer concentration. The onset of aggregate formation is shown by an 
abrupt change in the slope of the tangent curves with increasing polymer concentration. The CMC is used 
to characterize the thermodynamic stability of the polymeric micelles upon dilution in the bloodstream. 
CMC is among other things dependent on the nature and length of the hydrophobic block and length of 
hydrophilic block.32 The CMC values of HEAm-BC-based block copolymers were found to be lower than 
HEAm-EC-based block copolymers. (Table 4)  Most likely this is due to hydrophobicity and stacking 
interactions of the aromatic benzyl group, which suggests good stability. Moreover, a further decrease of 
CMC is observed with increasing length of the hydrophobic EC/BC segment. However, except for 
pHEAm64-pHEAmBC25, no difference in CMC values is observed for the polymers with distinct HEAm-BC 
block lengths. This can most likely be ascribed to the detection limit of the pyrene assay as at very low 
polymer concentrations, a relatively larger fraction of the pyrene probe will tend to distribute into the 
aqueous phase instead of the micelle core. Moreover, we observed that the nature of the hydrophilic block 
also has a significant influence on CMC. Block copolymer micelles based on PEG, show a much lower 
CMC and hence formed more stable nanoparticles in comparison to their pHEAm-counterparts. At present 
we do not have a clear explanation for this phenomenon which could be due to differences in polarity, 
flexibility, etc. This is subject of our ongoing investigations. 
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FIGURE 7: Intensity ratio of pyrene at 338 nm (I3) and 333 nm (I1) as a function of polymer concentration, determined 
by fluorescence spectrophotometry at 37 °C (n=3) 
 
 
TABLE 4. Numeric values for CMC of different polymers (n= 3) 
PolymerHEAm-EC CMC (mg/mL) PolymerHEAm-BC CMC (mg/mL) 
 pHEAm64-pHEAmEC26 0.081 ± 0.03 pHEAm64-pHEAmBC25 0.024 ± 0.002 
pHEAm64-pHEAmEC56 0.031 ± 0.002 pHEAm64-pHEAmBC68 0.0047 ± 0.0004 
pHEAm140-pHEAmEC88 0.028  ± 0.003 pHEAm140-pHEAmBC91 0.0051 ± 0.0004 
pHEAm140-pHEAmEC160 0.0075 ± 0.0002 pHEAm140-pHEAmBC172 0.0041 ± 0.0005 
PEG-pHEAmEC41 0.023 ± 0.004 PEG-pHEAmBC41 0.0036 ± 0.0006  
PEG-pHEAmEC81 0.0096 ± 0.003 PEG-pHEAmBC78 0.0033 ± 0.0003 
 
 
3.8. In vitro cellular uptake 
Rhodamine B octadecyl chloride (R18), a model red fluorescent dye, was used to investigate whether the 
nanoparticles are able to enhance intracellular delivery of a hydrophobic payload. For this purpose we 
used the SKOV-3 human ovarian cancer cell line. Block copolymers micelles were loaded with the dye by 
solvent displacement from ethanol into PBS. When adding the dye to PBS, immediate precipitation 
occurred. However, when the dye was added to a micelle formulation, no precipitation occurred, 
demonstrating that this hydrophobic dye was solubilized in the hydrophobic core of the micelles. 
Confocal microscopy was performed to determine whether the fluorescent payload was internalized by 
the cells or merely bound to the cell membrane. After pulsing with micelles, cells were fixated and stained 
with Hoechst and AlexaFluor488-conjugated phalloidin to visualize the cell nuclei and cell membrane, 
respectively. The confocal images in Figure 8 show that except for the blank, all micelle formulations 
afford intracellular delivery of the hydrophobic R18 payload.  
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FIGURE 8: Confocal microscopy image of SKOV-3 human ovarian cells pulsed for 16h with rhodamine loaded 
micelles (red fluorescence). Cell nuclei were stained in blue by Hoechst, and cell membrane was stained in green by 
AlexaFluor488 conjugated phalloidin.  
3.9. Drug formulation 
To investigate the potential of the block copolymers for solubilization of hydrophobic drug molecules, we 
opted for paclitaxel. Paclitaxel (PTX) is a potent anti-tumor agent, used for various malignancies among 
them ovarian and breast cancer.33  However, a major hurdle is the poor aqueous solubility (0.3 μg/mL) 
which hampers the delivery of therapeutic dosages. Taxol was the first clinical PTX formulation and 
comprise a mixture of Cremophor El (CrEL) and dehydrated ethanol (50:50). CrEL, a non-ionic surfactant, 
elicits a range of side effects, including serious hypersensitivity reactions, nephro-and neurotoxicity, which 
are dose limiting and require clinical intervention. 33–36 Therefore, alternative formulations for PTX were 
investigated and this led to the approval of Abraxane, a nanoparticle formulation of human serum albumin 
and PTX.37 The first approved polymeric micelle formulation of PTX is Genexol-PM that consist of an 
amphiphilic block copolymer of PEG en poly(D,L) lactide (PLA). 38 It is approved in South Korea and is 
undergoing clinical trials in the US. There are several other polymeric micelles that are developed and/or 
progressing in clinical trials, which show the potential as drug delivery system for the effective therapy of 
cancer and non-cancerous diseases.22,39 ,40,41,42 
The loading procedure of PTX in the micelles is described in section 2.15. The encapsulation efficiency 
(EE) and loading capacity (LC) were determined by UPLC (Figure 9). These data show that by increasing 
the core block length, both the EE and LC increase. Moreover, a higher encapsulation of the drug is 
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observed in the micelles with HEAm-BC as core-forming block, which can be explained by higher polymer-
drug compatibility due to strong Π-Π interactions between the aromatic groups of PTX and the HEAm-BC 
block. Also, micelles based on PEG, show more promising results, i.e. higher LC en EE in comparison to 
pHEAm-based micelles. These findings can be linked to the lower CMC values measured form PEG-
based micelles (Figure 7), which suggest that a more stable hydrophobic core, as formed by PEG-based 
micelles, is favorable for encapsulation of PTX. 
 
Figure 9: Calculated encapsulation efficiency (EE) and loading capacity (LC) of PTX-loaded micelles.  
 
3.10. In vitro cytotoxicity  
The in vitro cytotoxicity of PTX-loaded – and empty micelles was investigated by MTT-assay on SKOV-3 
cells. Abraxane, an albumin-bound formulation of paclitaxel and Genexol-PM, a PTX-loaded PEG−poly- 
(lactide) block copolymer micelle formulation, were used as control formulations. After 72 hours of 
incubation, the inhibitory effect of PTX on cell growth was measured. As shown in Figure 10A, no intrinsic 
toxicity is observed for all empty micelles within the tested concentration range (up to 1 mg/mL) which 
indicates good cytocompatibility of the block copolymers within the experimental window. PTX-loaded 
micelles show a dose-dependent increase in cytotoxicity, comparable to Abraxane and Genexol-PM 
(Figure 10B). The cytotoxic effect of PTX will most likely be the result of the dilution effect, diffusion of 
the drug out of the micelles (as at lower PTX concentration the polymer concentration will be below the 
CMC (Table S2)) and binding to other hydrophobic binding sites in the cell culture medium or within the 
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cell. To a much lower extent, degradation of the polymers could also contribute to the cytotoxic effect of 
PTX.  
  
Figure 10. (A) In vitro cytotoxicity of unloaded micelles on SKOV-3 cells after 72 h of incubation (n=3). (B) In vitro 
cytotoxicity of PTX-loaded micelles on SKOV-3 cells after 72 h of incubation (n=3). Abraxane and Genexol PM were 
used as control nanoformulations.  
 
 
4. Conclusions 
In this paper we introduced a novel class of degradable polyacrylamides based on the hydrophobic 
modification of the readily available hydrophilic N-(2-hydroxyethyl)acrylamide (HEAm). The pending 
hydroxyl group of HEAm was modified with either an ethyl or benzyl group via a hydrolytically sensitive 
carbonate ester. Degradation of the carbonate ester moieties results in the release of CO2 and 
ethanol/benzylalcohol as benign byproducts. Efficient RAFT polymerization of these monomers was 
observed and a library of well-defined block polymers with different degrees of polymerization (DP) was 
synthesized. The block copolymers formed micellar nanoparticles (10-100 nm) in PBS and could 
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efficiently solubilize hydrophobic compounds. The introduction of a benzyl carbonate ester side chain 
increased micellar stability and drug loading capacity. Moreover, PEG showed the most optimal 
performance in terms of micellar stability and drug loading capacity as well. Confocal microscopy showed 
that the micelles can efficiently deliver a hydrophobic payload to in vitro cultured cancer cells. Finally we 
also demonstrated efficient formulation of paclitaxel with an in vitro cancer cell killing performance 
comparable or even better than two commercial available PTX nanoformulations. In our ongoing research 
endeavours, the versatility of the RAFT approach will be further explored in the direction of core 
crosslinking and covalent drug ligation to ensure stability in the blood stream and in the direction of active 
targeting using small molecule ligand functionalized RAFT chain transfer agents. 
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Figure S1. 1H-NMR of CI-activated ethanol 
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Figure S2. 1H-NMR of HEAm-EC 
 
 
 
Figure S3. ESI-MS of HEAm-EC 
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Figure S4. 1H-NMR of CI-activated benzylalcohol 
 
 
 
Figure S5. 1H-NMR of HEAm-BC 
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Figure S6. ESI-MS of HEAm-BC 
 
 
Table S1. Supramolecular characteristics of synthesized block copolymers.  
Polymer Volume mean (nm)a  Đa 
pHEAm64-pHEAmEC26 10.99   0.36 
pHEAm64-pHEAmEC56 32.12  0.16 
pHEAm140-pHEAmEC88 44.63  0.036 
pHEAm140-pHEAmEC160 86.47  0.13 
PEG-pHEAmEC41 29.33  0/12 
PEG-pHEAmEC81 46.33  0.10 
pHEAm64-pHEAmBC25 27.40  0.26 
pHEAm64-pHEAmBC68 65.22  0.32 
pHEAm140-pHEAmBC91 94.69  0.40 
pHEAm140-pHEAmBC192 91.54  0.27 
PEG-pHEAmBC42 35.56  0/081 
PEG-pHEAmBC78 101.23  0.050 
a Numeric values of volume mean and Đ, measured by DLS at 25°C (n=3) 
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Table S2. Overview of CMC values and polymer concentrations in the samples used for 
the MTT assay. 
PTX-
concentration 
  pHEAM64-
pHEAMEC26 
 pHEAM64-
pHEAMBC25 
pHEAM64-
pHEAMEC56 
pHEAM64-
pHEAMBC68 
PEG-
pHEAMEC41 
PEG-
pHEAMBC42 
PEG-
pHEAMEC81 
PEG-
pHEAMBC78 
(μM) 
 
mg/mL mg/mL mg/mL mg/mL mg/mL mg/mL mg/mL mg/mL 
 
CMC 
(mg/mL) 
0.081 ± 0.03 0.024 ± 0.002 0.031 ± 0.002 0.0047 ± 
0.0004 
0.023 ± 0.004 0.0036 ± 
0.0006  
0.0096 ± 
0.003 
0.0033 ± 
0.0003           
2 
 
1,71 0,688 0,516 0,152 0,208 0,0368 0,042 0,032 
1 
 
0,855 0,344 0,258 0,076 0,104 0,0184 0,021 0,016 
0,1 
 
0,085 0,034 0,0258 0,0076 0,0104 0,00184 0,0021 0,0016 
0,01 
 
0,0085 0,0034 0,00258 0,00076 0,00104 0,000184 0,00021 0,00016 
0,001 
 
0,00085 0,00034 0,000258 0,000076 0,000104 0,0000184 0,000021 0,000016 
0,0001 
 
0,000085 0,000034 0,0000258 0,0000076 0,0000104 0,00000184 0,0000021 0,0000016 
0,00001 
 
0,0000085 0,0000034 0,00000256 0,0000076 0,00000104 0,000000184 0,00000021 0,00000016 
 
 
 
 
 
